Special Issue

Neuropathic Pain Pharmacology: Efforts to Cure A Deranged, Hyper-Sensitive System

Message from the Guest Editors

Neuropathic pain is a pathology per se. It originates from a lesion or disease of the somatosensory nervous system that evokes dysfuntional, plastic modifications of tissues leading to pain persistence. The maladaptive response of the complex cell network dedicated to the trasmission and perception of pain dramatically upsets nociception as well as the physiological substrate of classical analgesics. A novel way of thinking is necessary to plan and develop effective pain relievers. New targets in sensitive neurons, the relevance of glial cells, and the pivotal role of the central nervous system have emerged in recent years in neuropathic pain physiopathology shedding light into the darkness. Nevertheless, patients need effective drugs to relieve pain and, even more, drugs able to restore the altered nervous system and stop chronicization. Thus, this Special Issue is intended to collect experimental results about innovative approaches and, of course, *molecules* able to control pain as monotherapy or as adjuvant to other pain killers.

Guest Editors

Dr. Lorenzo Di Cesare Mannelli

Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Pharmacology and Toxicology Section, University of Florence, 50139 Florence, Italy

Dr. Alessandra Pacini

Department of Experimental and Clinical Medicine, Anatomy Section, School of Human Health Sciences, University of Florence, 50121 Florence, Italy

Deadline for manuscript submissions

closed (1 May 2020)

Molecules

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed

mdpi.com/si/33808

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

mdpi.com/journal/molecules

Molecules

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed

mdpi.com/journal/molecules

MDPI

About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt
Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).